

Filed on behalf of Dr. Reddy's Laboratories, Ltd.
and Dr. Reddy's Laboratories, Inc.

By: Jeffery B. Arnold
jarnold@cantorcolburn.com
Cantor Colburn LLP
1180 Peachtree Street, Suite 2050
Atlanta, Georgia 30309
Telephone: (404) 607-9991
Facsimile: (404) 607-9981

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES, LTD. AND DR. REDDY'S
LABORATORIES, INC.,
Petitioners,

v.

INDIVIOR UK LIMITED,
Patent Owner.

Patent No. 8,475,832
Issue Date: July 2, 2013
Title: SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
Inter Partes Review No. IPR2016-XXXXX

**PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 8,475,832**

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. BACKGROUND	1
A. Brief Overview of the '832 Patent	1
B. Brief Overview of the Prosecution History	3
III. GROUNDS FOR STANDING (§ 42.104(A))	6
IV. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8	6
A. Real Party-in-Interest (§ 42.8(b)(1))	6
B. Related Proceedings (§ 42.8(b)(2))	6
C. Lead and Backup Counsel (§ 42.8(b)(3))	10
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND IDENTIFICATION OF THE CHALLENGE (§ 42.104(B))	11
VI. LEVEL OF ORDINARY SKILL IN THE ART	13
VII. THE CHALLENGED CLAIMS OF THE '832 PATENT	13
VIII. CLAIM CONSTRUCTION	15
IX. SCOPE AND CONTENT OF THE PRIOR ART	15
A. WO2008/040534 (“LabTec”) (Ex. 1007)	15
B. WO 2008/025791 (“Oksche”) (Ex. 1005)	16
C. U.S. Patent No. 7,357,891 (“Yang”) (Ex. 1006)	16
D. Suboxone [®] Sublingual Tablets (Label and SBOA, Exs. 1008 and 1009)	17
E. U.S. Patent Publication 2005/0085440 (“Birch”) (Ex. 1004)	22
F. The '055 Publication (Ex. 1010)	23

;

X.	DETAILED EXPLANATION OF THE GROUNDS FOR UNPATENTABILITY	24
A.	Ground 1: Claims 1-2, 4-7, and 9-10 are Invalid Under 35 U.S.C. § 103(a) as Being Obvious Over LabTec in View of Yang, the Suboxone [®] 2002 Label, SBOA, and Birch.....	24
1.	The film dosage limitations	24
2.	The buffer and pH range limitations.....	27
B.	Ground 2: Claims 3 and 11-12 are Invalid Under 35 U.S.C. § 103(a) as Being Obvious Over LabTec in View of Yang, the Suboxone [®] 2002 Label, SBOA, Birch, and the '055 Publication.....	39
C.	Ground 3: Claims 1-2, 4-7, and 9-10 are Invalid Under 35 U.S.C. § 103(a) as Being Obvious Over Oksche in View of Yang, Birch, the Suboxone [®] 2002 Label, and SBOA.....	40
1.	The film dosage limitations	40
2.	The buffer and pH range limitations.....	43
D.	Ground 4: Claims 3 and 11-12 are Invalid Under 35 U.S.C. § 103(a) as Being Obvious Over Oksche in View of Yang, Birch, the Suboxone [®] 2002 Label, SBOA, and the '055 Publication.....	49
XI.	CONCLUSION.....	50

PETITIONERS' EXHIBIT LIST

Exhibit No.	Reference
1001	U.S. Patent No. 8,475,832 (filed August 7, 2009) (“’832 patent”)
1002	File History, U.S. Patent No. 8,475,832
1003	Expert Declaration of Metin Çelik, Ph.D., Relating to U.S. Patent No. 8,475,832 (“Çelik Decl.”)
1004	U.S. Patent Application Publication 2005/0085440 (published April 21, 2005) (“Birch”)
1005	WO 2008/025791 (published March 6, 2008) (“Oksche”)
1006	U.S. Patent No. 7,357,891 (published December 23, 2004) (issued April 15, 2008) (“Yang”)
1007	WO 2008/040534 (published April 10, 2008) (“LabTec”)
1008	Suboxone [®] Label
1009	Suboxone [®] Tablet Summary Basis of Approval (“SBOA”)
1010	U.S. Patent Application Publication No. 2005/0037055 (“the ’055 publication”)
1011	European Medicines Agency Initial Marketing-Authorisation Document, Scientific Discussion, Oct. 19, 2006 for Suboxone [®] sublingual tablets (“EMA”)
1012	J.P. Cassidy et al., <i>Controlled Buccal Delivery of Buprenorphine</i> , 25 J. Controlled Release 21 (1993)
1013	Rex M. C. Dawson et al., <i>Data for Biochemical Research</i> (3d ed. 1986)
1014	Domenic A. Ciraulo et al., <i>Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets</i>

...

	<i>in Dose-Escalation Trials</i> , 46 J. Clinical Pharmacology 179 (2006)
1015	C. Nora Chiang & Richard L. Hawks, <i>Pharmacokinetics of the Combination Tablet of Buprenorphine and Naloxone</i> , 70 Drug & Alcohol Dependence S39 (2003)
1016	Campbell et al., <i>The History of the Development of Buprenorphine as an Addiction Therapeutic</i> , 1248 Ann. N.Y. Acad. Sc. (Issue: Addiction Reviews), 124 (2012) (“Campbell”)
1017	Bullingham et al., <i>Sublingual Buprenorphine Used Postoperatively: Clinical Observations and Preliminary Pharmacokinetic Analysis</i> , 12 Br. J. Clinical Pharmacology 117 (1981)
1018	U.S. Patent App. Pub. No. US 2010/0087470
1019	U.S. Patent No. 4,582,835
1020	Center for Drug Evaluation and Research, Approval Package for App. No. 22-410/S006/S007 (approval date 8/10/12) (“Film Approval Package”)
1021	Encyclopedia of Pharmaceutical Technology, 2nd ed., Vol. I, Drug Delivery—Buccal Route (McElnay et al.) (“McElnay”)
1022	U.S. Patent No. 5,288,497 (“Stanley”)
1023	Declaration by Marlene Bobka (“Bobka Decl.”)
1024	Parkhurst A. Shore et al., <i>The Gastric Secretion of Drugs: A pH Partition Hypothesis</i> , 119 J. Pharmacology Exp. Ther. 361 (1957)
1025	Curriculum Vitae of Metin Çelik, Ph.D.
1026	List of Materials Considered by Metin Çelik, Ph.D.
1027	<i>The Theory and Practice of Industrial Pharmacy</i> (L. Lachman, Ph.D.) (1986)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.